Glucagon: role in the hyperglycemia of diabetes mellitus.
Glucagon suppression by somatostatin reduces or abolishes hyperglycemia in dogs made insulin-deficient by somatostatin, alloxan, or total pancreatectomy. This suggests that the development of severe diabetic hyperglycemia requires the presence of glucagon, whether secreted by pancreatic or newly identified gastrointestinal A cells, as well as a lack of insulin. Glucagon suppression could improve therapeutic glucoregulation in diabetes.
D000818:Animals; D001120:Arginine / Q000494:pharmacology; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000150:complications; D004285:Dogs; D005934:Glucagon / Q000502:physiology*; D013007:Growth Hormone-Releasing Hormone / Q000037:antagonists & inhibitors*; D006943:Hyperglycemia / Q000209:etiology; D007328:Insulin / Q000494:pharmacology; D009842:Oligopeptides / Q000494:pharmacology; D010180:Pancreatectomy
D007328:Insulin; D009842:Oligopeptides; D005934:Glucagon; D013007:Growth Hormone-Releasing Hormone; D001120:Arginine